Regorafenib in Combination with First‐Line Chemotherapy for Metastatic Esophagogastric Cancer

BACKGROUND: Angiogenesis is critical to gastroesophageal adenocarcinoma growth and metastasis. Regorafenib is a multikinase inhibitor targeting angiogenic and stromal receptor tyrosine kinases. We evaluated whether regorafenib augments the antitumor effect of first‐line chemotherapy in metastatic es...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Moy, Ryan H., Dos Santos Fernandes, Gustavo, Jonsson, Philip, Chou, Joanne F., Basunia, Azfar, Ku, Geoffrey Y., Chalasani, Sree B., Boyar, Michelle S., Goldberg, Zoe, Desai, Avni M., Gabler, Amelia, Berger, Michael F., Tang, Laura H., Hechtman, Jaclyn F., Kelsen, David P., Schattner, Mark, Ilson, David H., Solit, David B., Taylor, Barry S., Schultz, Nikolaus, Capanu, Marinela, Janjigian, Yelena Y.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964136/
https://ncbi.nlm.nih.gov/pubmed/31570517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0492
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares